Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer

• Published in: Cancer immunology research Vol. 4; no. 4; p. 289
• Main Authors: Nishino, Mizuki, Chambers, Emily S, Chong, Curtis R, Ramaiya, Nikhil H, Gray, Stacy W, Marcoux, J Paul, Hatabu, Hiroto, Jänne, Pasi A, Hodi, F Stephen, Awad, Mark M
• Format: Journal Article
• Language: English
• Published: United States 01.04.2016
• Subjects: Aged; Aged, 80 and over; Anti-Bacterial Agents - therapeutic use; Antibodies, Monoclonal - adverse effects; Antineoplastic Agents - adverse effects; Carcinoma, Non-Small-Cell Lung - complications; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Female; Humans; Lung Neoplasms - complications; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Male; Neoplasm Staging; Pneumonia - diagnosis; Pneumonia - drug therapy; Pneumonia - etiology; Prednisolone - therapeutic use; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Tomography, X-Ray Computed; Treatment Outcome
• ISSN: 2326-6074
• DOI: 10.1158/2326-6066.cir-15-0267

The recent approval of two PD-1 inhibitors for the treatment of non-small cell lung cancer (NSCLC) has rapidly led to the widespread use of these agents in oncology practices. Pneumonitis has been recognized as a potentially life-threatening adverse event among NSCLC patients treated with PD-1 inhibitors; however, the detailed clinical and radiographic manifestations of this entity remain to be described. We report on two cases of anti-PD-1 pneumonitis in advanced NSCLC patients treated with nivolumab after its FDA approval. Both patients presented with ground-glass and reticular opacities and consolidations in a peripheral distribution on CT, demonstrating a radiographic pattern of cryptogenic organizing pneumonia. Consolidations were extensive and rapidly developed within 8 weeks of therapy in both cases. Both patients were treated with corticosteroids with subsequent improvement of respiratory symptoms and radiographic findings. One patient experienced recurrent pneumonitis after completing corticosteroid taper, or a "pneumonitis flare," in the absence of nivolumab retreatment, with subsequent improvement upon corticosteroid readministration. With the increasing use of immune checkpoint inhibitors in a growing number of tumor types, awareness of the radiographic and clinical manifestations of PD-1 inhibitor-related pneumonitis will be critical for the prompt diagnosis and management of this potentially serious adverse event.